+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Anal Cancer - Pipeline Review, H1 2017

  • ID: 4189176
  • Report
  • March 2017
  • 183 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Advaxis Inc
  • Atara Biotherapeutics Inc
  • BeiGene Ltd
  • Eli Lilly and Company
  • ISA Pharmaceuticals BV
  • Ono Pharmaceutical Co Ltd
  • MORE
Anal Cancer - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H1 2017, provides an overview of the Anal Cancer (Oncology) pipeline landscape.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Anal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 3, 5 and 2 respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Advaxis Inc
  • Atara Biotherapeutics Inc
  • BeiGene Ltd
  • Eli Lilly and Company
  • ISA Pharmaceuticals BV
  • Ono Pharmaceutical Co Ltd
  • MORE
Introduction

Anal Cancer - Overview

Anal Cancer - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Anal Cancer - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anal Cancer - Companies Involved in Therapeutics Development

Advaxis Inc

Amgen Inc

Atara Biotherapeutics Inc

Bayer AG

BeiGene Ltd

Cell Medica Ltd

Eli Lilly and Company

Immunovaccine Inc

ISA Pharmaceuticals BV

Merck & Co Inc

Millennium Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Oryx GmbH & Co KG

PDS Biotechnology Corp

Sun Pharma Advanced Research Company Ltd

Taiwan Liposome Company Ltd

Anal Cancer - Drug Profiles

alisertib - Drug Profile

ATA-368 - Drug Profile

axalimogene filolisbac - Drug Profile

BAY-1125976 - Drug Profile

BGBA-317 - Drug Profile

cisplatin - Drug Profile

CMD-004 - Drug Profile

CUE-101 - Drug Profile

CUE-201 - Drug Profile

DPXE-7 - Drug Profile

ISA-101 - Drug Profile

nivolumab - Drug Profile

paclitaxel albumin free - Drug Profile

panitumumab - Drug Profile

PDS-0101 - Drug Profile

pembrolizumab - Drug Profile

prexasertib - Drug Profile

TLC-388 - Drug Profile

Vicoryx - Drug Profile

Anal Cancer - Dormant Projects

Anal Cancer - Discontinued Products

Anal Cancer - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Anal Cancer, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Anal Cancer - Pipeline by Advaxis Inc, H1

Anal Cancer - Pipeline by Amgen Inc, H1

Anal Cancer - Pipeline by Atara Biotherapeutics Inc, H1

Anal Cancer - Pipeline by Bayer AG, H1

Anal Cancer - Pipeline by BeiGene Ltd, H1

Anal Cancer - Pipeline by Cell Medica Ltd, H1

Anal Cancer - Pipeline by Eli Lilly and Company, H1

Anal Cancer - Pipeline by Immunovaccine Inc, H1

Anal Cancer - Pipeline by ISA Pharmaceuticals BV, H1

Anal Cancer - Pipeline by Merck & Co Inc, H1

Anal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1

Anal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1

Anal Cancer - Pipeline by Oryx GmbH & Co KG, H1

Anal Cancer - Pipeline by PDS Biotechnology Corp, H1

Anal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H1

Anal Cancer - Pipeline by Taiwan Liposome Company Ltd, H1

Anal Cancer - Dormant Projects, H1

Anal Cancer - Discontinued Products, H1

List of Figures:

Number of Products under Development for Anal Cancer, H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
4 of 5
  • Advaxis Inc
  • Amgen Inc
  • Atara Biotherapeutics Inc
  • Bayer AG
  • BeiGene Ltd
  • Cell Medica Ltd
  • Eli Lilly and Company
  • Immunovaccine Inc
  • ISA Pharmaceuticals BV
  • Merck & Co Inc
  • Millennium Pharmaceuticals Inc
  • Ono Pharmaceutical Co Ltd
  • Oryx GmbH & Co KG
  • PDS Biotechnology Corp
  • Sun Pharma Advanced Research Company Ltd
  • Taiwan Liposome Company Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll